UBA – Preclinical and clinical development of the ubiquitin-proteasome system inhibitor as an innovative drug used in cancer treatment.

Funding Agreement No.: POIR.01.02.00-00-0009/17-00 under Measure 1.2: “Sectoral R&D programmes”
Date of the contract conclusion: 07.11.2017.

The aim of the project is designing an innovative, effective and safe drug candidate used in treatment of selected solid tumours. According to the WHO, tumours are the most common type of diseases of affluence (World Cancer Report, 2014). The latest studies focus on the role of the ubiquitin-proteasome system (UPS), especially ubiquitin-activating enzyme (UAE), in regulating protein production, and thus in survival of cancer cells. Suppressing the key enzyme in protein ubiquitination may constitute an effective alternative in treatment of solid tumours. The currently used molecules with a similar pharmacological profile are characterised by numerous adverse effects, are administered intravenously and show no effectiveness in treatment of solid tumours, which makes a search for new therapies necessary. The project duration is 45 months. The first stages include: lead compound synthesis, development of analytical methods and the final drug form. We will also conduct analyses advancing study of the mechanism and exploring biomarkers of response to therapy. Furthermore, in vivo and toxicology screenings have been planned in order to ensure the effectiveness and safety of the compound. A test for selecting patients for clinical trials will be designed and validated. The last stages of the project include phase 1/2 clinical trials with patients with solid tumours. The result of the project will be an innovative and fully developed drug inhibiting UAE with validated efficacy and safety profile for patients.

Total value of the UBA project:
37 472 533,50 PLN
Total value of funding: 25 646 443,69 PLN